Even transformative therapies fail if the dosing is wrong.
Innovation isn't simply about moving faster. It's about knowing what to introduce, when to introduce it, and how much change an organization can successfully absorb.
In Healthcare's Digital Dawn, the greatest risk isn't underestimating technology. It's overestimating an organization's capacity to adopt it.
The therapeutic window of opportunity is wide open. But flooding teams with change rarely accelerates transformation. More often, it creates resistance. Technology evolves at digital speed. People adopt change at human speed.
If innovation were a medicine, we'd never prescribe the maximum dose on Day One. We'd start deliberately, monitor carefully, learn continuously, and adjust as confidence grows. Leadership should be no different.
The prescription matters. But so does the dose.
Sequence Before You Scale.
Business Unusual doesn't reward organizations that launch the most initiatives. It rewards those that build capability before complexity.
Innovation succeeds when people understand it, trust it, and believe they can use it confidently. That's why sequencing matters as much as strategy.
Ask yourself:
Are we introducing innovation faster than our people can absorb it?
Have we built trust before expecting adoption?
Are we scaling capability—or simply scaling technology?
Are we creating momentum—or fatigue?
The goal isn't to innovate more.
It's to innovate in a way people can successfully adopt.
BOLD VOICES SHAPING WHAT'S NEXT
“Innovation doesn't mean going to scale overnight. It means testing, learning, iterating.
You don't build trust in healthcare through big launches — you earn it through transparency, evidence, and consistency over time.”
JULIE FISHMAN - PHARMACIST | HEALTHCARE EXECUTIVE | DIGITAL HEALTH CHAMPION
Build Trust Before Velocity.
Technology can move overnight. Healthcare can't.
Every meaningful innovation must earn the confidence of patients, clinicians, regulators, payers, and health systems. That's not bureaucracy. That's healthcare doing what healthcare is designed to do—protect people.
The leaders who succeed won't fight this reality.
They'll embrace it.
Because trust isn't the price innovation pays.
Trust is the accelerator that allows innovation to scale.
The Best Innovation Bridges Two Worlds.
Healthcare has something technology desperately needs.
Trust.
Technology has something healthcare desperately needs.
Speed.
The future belongs to leaders who can combine both.
Move with the curiosity and experimentation of technology. Lead with the evidence, empathy, and discipline of healthcare.
Innovation isn't about choosing between agility and rigor. It's about mastering both.
BOLD VOICES SHAPING WHAT'S NEXT
“I think of innovation like a potent therapy: the dosage, timing, and combination with other 'agents' matter.
Get it right, and you energize a team to move toward a bold future.
Get it wrong, and you risk burnout or resistance.”
PATRICK NOWLIN - PHARMA EXECUTIVE | DIGITAL HEALTHCARE CEO
The Final Dose
Innovation isn't the goal. Adoption is.
Every successful therapy depends on selecting the right patient, the right dose, the right timing, and adjusting as new evidence emerges.
Leadership follows exactly the same principle.
The organizations that thrive won't be those chasing every new technology.
They'll be the ones who know how to sequence change, build trust, and continuously increase their organization's capacity to innovate.
Innovation isn't a one-time dose. It's a carefully managed therapy that is prescribed wisely.
FOUNDER, DOSE OF INNOVATION
Behind Dose of Innovation is Dr Alex Condoleon, a healthcare executive, innovator, and student of leadership in times of accelerated change.
Through articles, frameworks, the Frontier Series and Dose Response conversations, Alex explores the ideas, technologies, and leadership shifts reshaping healthcare—translating complexity into practical insights for leaders navigating Healthcare's Digital Dawn.
His work sits at the intersection of healthcare, technology, leadership, and human behavior, exploring what it takes to lead with curiosity, courage, and confidence in times of accelerated change.
Because we're still in Phase I.